Nigel Garrett

Dados Biográficos

ID	7429538
NOME	Nigel Garrett
PRENOMES	Nigel
SOBRENOME	Garrett
ASSINATURA	GARRETT N
AFILIAÇÕES	Centre for the AIDS Programme of Research in South Africa
ORCID	0000-0002-4530-234X
VERIFICADO	Sim
TOTAL DE OBRAS	16
TOTAL DE CITAÇÕES	0
TOTAL COMO AUTOR	16
TOTAL COMO EDITOR	0
PRIMEIRO ANO DE PUBLICAÇÃO	2013
ANO MAIS RECENTE DE PUBLICAÇÃO	2026
ÍNDICE H	0

Trends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa
Open AccessSanele S Mbeje, Lilishia Gounder et al.ARTICLEPLOS Global Public Health2026
Advanced HIV disease (AHD), treatment interruption and viraemia remain key challenges to effectiveness of HIV programmes in South Africa. Understanding the trends of these measures and their variation across geographic regions can inform more targeted and responsive interventions. We conducted a retrospective cohort study using routine, de-identified data from TIER.Net, a national HIV electronic register. We curated data from 116 primary care cli…
Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register Tier.Net
Open AccessLisanthini Naidu, Johan van der Molen et al.ARTICLEPLOS Global Public Health2026
Three Interlinked Electronic Register (TIER.Net) is South Africa’s national electronic HIV patient database, used to monitor antiretroviral therapy (ART) delivery and laboratory results. However, few published evaluations have quantified TIER.Net data quality relative to national sources. We aimed to evaluate how well decentralised ART referral and laboratory result data are captured in TIER.Net. We conducted a retrospective analysis comparing TI…
Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme
Open AccessJienchi Dorward, Kwena Tlhaku et al.ARTICLEPLOS Global Public Health2026
Community antiretroviral therapy (ART) delivery programmes allow people with HIV (PWH) to collect treatment nearer to home instead of from clinics. However, delays in laboratory-based viral load (VL) testing can prevent timely community ART prescription renewals. We aimed to determine if clinic point-of-care VL testing could expedite community ART prescription renewals within the Centralised Chronic Medication Dispensing and Distribution programm…
Acceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring
Ashley R Bardon, Ashley Bardon et al.ARTICLEAIDS Care2026
Real-time, urine tenofovir testing may allow for clinic-based monitoring of adherence to antiretroviral therapy (ART). We aimed to assess (1) the acceptability of monthly point-of-care urine tenofovir testing over the first five months following ART initiation and (2) perspectives on the implementation of point-of-care urine tenofovir testing among people living with HIV (PLWH) and healthcare providers participating in a randomized controlled tri…
Spatial mapping of HIV testing and antiretroviral therapy initiation uptake among the adolescents and youth in rural KwaZulu-Natal, South Africa
Open AccessMulugeta Shegaze Shimbre, A Gibbs et al.ARTICLEAIDS Care2026
This study investigated the spatial distribution of HIV testing and antiretroviral therapy initiation among adolescents and youth in rural KwaZulu-Natal, South Africa, to inform the optimal allocation of HIV services. The sample included 5,352 participants aged 13-35 years from nested cohort studies within Africa's largest population-based prospective cohorts, with global positioning system data collected for all homesteads. HIV testing prevalenc…
Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa
Open AccessKwabena Asare, Lara Lewis et al.ARTICLEBMJ Global Health2025
INTRODUCTION: We investigated the impact of increasing CD4 count eligibility for antiretroviral therapy (ART) initiation on advanced HIV disease (AHD) and tuberculosis (TB) prevalence and incidence among people living with HIV (PLHIV) in South Africa. METHODS: We conducted an interrupted time series analysis with de-identified data of PLHIV aged ≥15 years initiating ART between April 2012 and February 2020 at 65 primary healthcare clinics in KwaZ…
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from Sars-CoV-2 acquisition in Africa
Open AccessNonhlanhla N Mkhize, Shuying Sue Li et al.ARTICLEPLOS Global Public Health2025
COVID-19 has affected millions worldwide. Research characterized immune responses of individuals who acquired SARS-CoV-2 and identified co-factors, such as HIV, associated with greater likelihood of poor clinical outcomes. SARS-CoV-2-specific neutralizing antibodies (nAbs) are a strong correlate of protection but their elicitation in people living with HIV (PLWH), and particularly in southern Africa, is less well characterized. HVTN 405/HPTN 1901…
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Open AccessCatherine Riou, Jinal N Bhiman et al.ARTICLEPLOS Global Public Health2024
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 …
Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during Covid-19 in South Africa
Open AccessKwena Tlhaku, Lindani Msimango et al.ARTICLEPLOS Global Public Health2024
During the COVID-19 pandemic, the South African Centralized Chronic Medicines Dispensing and Distribution (CCMDD) programme, adapted to include extended 12-month antiretroviral therapy (ART) prescriptions, 3-months ART refills and earlier eligibility criteria at 6-months after ART initiation. We aimed to explore the experiences of healthcare workers (HCWs) in implementing these adaptations, and to understand the overall impact of COVID-19 on CCMD…
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa
Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…
Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa
Open AccessSheila O Ojeaburu, Jienchi Dorward et al.ARTICLEAIDS and Behavior2024
We examined the impact of past-year intimate partner violence (IPV) on HIV outcomes among women living with HIV (WLHIV) in Durban, South Africa. We assessed past-year IPV using the WHO Violence Against Women Questionnaire. We conducted logistic regression to assess associations between demographic variables and IPV at baseline, and between IPV at baseline and longitudinal HIV outcomes. Among 235 WLHIV, 17% reported past-year emotional, physical, …
The impact of the Covid-19 lockdown on HIV care in 65 South African primary care clinics
Open AccessJienchi Dorward, Thokozani Khubone et al.ARTICLEThe Lancet HIV2021
BACKGROUND: The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and treatment in KwaZulu-Natal, South Africa, where 1·7 million people are living with HIV. METHODS: In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care clinics in KwaZulu-Natal province…
Acceptability of Early Antiretroviral Therapy Among South African Women
Open AccessNigel Garrett, Emily Norman et al.ARTICLEAIDS and Behavior2017
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting
Open AccessNivashnee Naicker, Ayesha B M Kharsany et al.ARTICLEAIDS and Behavior2015
Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the Caprisa 002 Acute Infection Study
Open AccessAndrew Tomita, Nigel Garrett et al.ARTICLEAIDS and Behavior2014
Health-Related Quality of Life Dynamics of HIV-positive South African Women up to ART Initiation
Open AccessAndrew Tomita, Nigel Garrett et al.ARTICLEAIDS and Behavior2013

Health-Related Quality of Life Dynamics of HIV-positive South African Women up to ART Initiation
Open AccessAndrew Tomita, Nigel Garrett et al.ARTICLEAIDS and Behavior2013
Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the Caprisa 002 Acute Infection Study
Open AccessAndrew Tomita, Nigel Garrett et al.ARTICLEAIDS and Behavior2014
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting
Open AccessNivashnee Naicker, Ayesha B M Kharsany et al.ARTICLEAIDS and Behavior2015
Acceptability of Early Antiretroviral Therapy Among South African Women
Open AccessNigel Garrett, Emily Norman et al.ARTICLEAIDS and Behavior2017
The impact of the Covid-19 lockdown on HIV care in 65 South African primary care clinics
Open AccessJienchi Dorward, Thokozani Khubone et al.ARTICLEThe Lancet HIV2021
BACKGROUND: The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and treatment in KwaZulu-Natal, South Africa, where 1·7 million people are living with HIV. METHODS: In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care clinics in KwaZulu-Natal province…
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Open AccessCatherine Riou, Jinal N Bhiman et al.ARTICLEPLOS Global Public Health2024
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 …
Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during Covid-19 in South Africa
Open AccessKwena Tlhaku, Lindani Msimango et al.ARTICLEPLOS Global Public Health2024
During the COVID-19 pandemic, the South African Centralized Chronic Medicines Dispensing and Distribution (CCMDD) programme, adapted to include extended 12-month antiretroviral therapy (ART) prescriptions, 3-months ART refills and earlier eligibility criteria at 6-months after ART initiation. We aimed to explore the experiences of healthcare workers (HCWs) in implementing these adaptations, and to understand the overall impact of COVID-19 on CCMD…
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa
Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…
Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa
Open AccessSheila O Ojeaburu, Jienchi Dorward et al.ARTICLEAIDS and Behavior2024
We examined the impact of past-year intimate partner violence (IPV) on HIV outcomes among women living with HIV (WLHIV) in Durban, South Africa. We assessed past-year IPV using the WHO Violence Against Women Questionnaire. We conducted logistic regression to assess associations between demographic variables and IPV at baseline, and between IPV at baseline and longitudinal HIV outcomes. Among 235 WLHIV, 17% reported past-year emotional, physical, …
Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa
Open AccessKwabena Asare, Lara Lewis et al.ARTICLEBMJ Global Health2025
INTRODUCTION: We investigated the impact of increasing CD4 count eligibility for antiretroviral therapy (ART) initiation on advanced HIV disease (AHD) and tuberculosis (TB) prevalence and incidence among people living with HIV (PLHIV) in South Africa. METHODS: We conducted an interrupted time series analysis with de-identified data of PLHIV aged ≥15 years initiating ART between April 2012 and February 2020 at 65 primary healthcare clinics in KwaZ…
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from Sars-CoV-2 acquisition in Africa
Open AccessNonhlanhla N Mkhize, Shuying Sue Li et al.ARTICLEPLOS Global Public Health2025
COVID-19 has affected millions worldwide. Research characterized immune responses of individuals who acquired SARS-CoV-2 and identified co-factors, such as HIV, associated with greater likelihood of poor clinical outcomes. SARS-CoV-2-specific neutralizing antibodies (nAbs) are a strong correlate of protection but their elicitation in people living with HIV (PLWH), and particularly in southern Africa, is less well characterized. HVTN 405/HPTN 1901…
Trends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa
Open AccessSanele S Mbeje, Lilishia Gounder et al.ARTICLEPLOS Global Public Health2026
Advanced HIV disease (AHD), treatment interruption and viraemia remain key challenges to effectiveness of HIV programmes in South Africa. Understanding the trends of these measures and their variation across geographic regions can inform more targeted and responsive interventions. We conducted a retrospective cohort study using routine, de-identified data from TIER.Net, a national HIV electronic register. We curated data from 116 primary care cli…
Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register Tier.Net
Open AccessLisanthini Naidu, Johan van der Molen et al.ARTICLEPLOS Global Public Health2026
Three Interlinked Electronic Register (TIER.Net) is South Africa’s national electronic HIV patient database, used to monitor antiretroviral therapy (ART) delivery and laboratory results. However, few published evaluations have quantified TIER.Net data quality relative to national sources. We aimed to evaluate how well decentralised ART referral and laboratory result data are captured in TIER.Net. We conducted a retrospective analysis comparing TI…
Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme
Open AccessJienchi Dorward, Kwena Tlhaku et al.ARTICLEPLOS Global Public Health2026
Community antiretroviral therapy (ART) delivery programmes allow people with HIV (PWH) to collect treatment nearer to home instead of from clinics. However, delays in laboratory-based viral load (VL) testing can prevent timely community ART prescription renewals. We aimed to determine if clinic point-of-care VL testing could expedite community ART prescription renewals within the Centralised Chronic Medication Dispensing and Distribution programm…
Acceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring
Ashley R Bardon, Ashley Bardon et al.ARTICLEAIDS Care2026
Real-time, urine tenofovir testing may allow for clinic-based monitoring of adherence to antiretroviral therapy (ART). We aimed to assess (1) the acceptability of monthly point-of-care urine tenofovir testing over the first five months following ART initiation and (2) perspectives on the implementation of point-of-care urine tenofovir testing among people living with HIV (PLWH) and healthcare providers participating in a randomized controlled tri…
Spatial mapping of HIV testing and antiretroviral therapy initiation uptake among the adolescents and youth in rural KwaZulu-Natal, South Africa
Open AccessMulugeta Shegaze Shimbre, A Gibbs et al.ARTICLEAIDS Care2026
This study investigated the spatial distribution of HIV testing and antiretroviral therapy initiation among adolescents and youth in rural KwaZulu-Natal, South Africa, to inform the optimal allocation of HIV services. The sample included 5,352 participants aged 13-35 years from nested cohort studies within Africa's largest population-based prospective cohorts, with global positioning system data collected for all homesteads. HIV testing prevalenc…